The field of corneal regenerative medicine reached a defining moment in October 2025, when surgeons at Rambam Medical Centre in Haifa, Israel completed what has been reported as the world’s first successful transplant of a 3D-bioprinted functional cornea. That single procedure has since accelerated the timeline for bioprinted cornea transplant clinical trials in 2026, with Phase II work now underway and regulatory agencies on two continents engaged in parallel review.
This article examines how corneal tissue engineering arrived at that milestone, what the Phase II trial design looks like, and how lessons from corneal bioprinting are informing adjacent work in musculoskeletal and multi-organ regenerative medicine.
Why the Cornea Was an Ideal First Target
The cornea holds several biological properties that made it a logical early focus for functional bioprinting rather than more vascular, structurally complex organs.
Structural simplicity relative to other organs. The adult human cornea is approximately 0.5 mm thick at center and consists of five distinct layers: the epithelium, Bowman’s layer, the stroma, Descemet’s membrane, and the endothelium. The stroma — which constitutes roughly 90% of corneal thickness — is composed primarily of type I collagen arranged in precise orthogonal lamellae. This highly ordered but relatively cell-sparse architecture is technically demanding to replicate, but it lacks the branching vasculature that makes bioprinting organs like the liver or kidney so challenging.
Immune privilege. The cornea is avascular and relies on diffusion from the aqueous humor and tear film for nutrient exchange. This immune-privileged status reduces host rejection risk compared to highly vascularized grafts and simplifies post-operative immunosuppression protocols.
A documented shortage. Corneal transplantation (keratoplasty) is among the most commonly performed transplant procedures globally, yet the supply of suitable donor tissue falls short of demand in many regions, particularly across sub-Saharan Africa, South Asia, and parts of Latin America. A reproducible bioprinted alternative addresses a genuine clinical gap.
The Bioink and Printing Approach
While the full technical protocol from the October 2025 procedure has not been published in peer-reviewed form as of mid-2026, the Rambam team has stated that their bioink combined decellularized corneal stromal matrix with patient-derived limbal stromal cells. This approach builds on a body of earlier research — including work from Newcastle University and multiple Israeli academic medical centres — that established decellularized extracellular matrix (dECM) bioinks as superior to pure collagen or alginate formulations for maintaining keratocyte viability and achieving the light-scattering properties necessary for optical transparency.
The printing method was extrusion-based, with parameters tuned to preserve cell viability while achieving sub-millimetre layer resolution approximating native stromal lamellation. Post-print, the construct was matured in a bioreactor under conditions designed to promote collagen fibril organization and keratocyte differentiation before implantation.
The use of patient-derived cells is significant: it positions this approach as personalized medicine rather than off-the-shelf allotransplantation, with downstream implications for immunosuppression burden and long-term graft survival.
For context on how scaffold materials are evolving to meet batch-consistency challenges, see decellularized ECM scaffolds in tissue engineering.
Phase I to Phase II: What the Transition Involved
The October 2025 procedure built on a Phase I trial assessing safety in a small cohort. Primary Phase I endpoints included freedom from graft rejection at six months, maintenance of intraocular pressure within normal range, and absence of significant corneal haze. Those thresholds were apparently met, enabling advancement.
Phase II trials for advanced therapy medicinal products (ATMPs) — the European Medicines Agency classification that applies to tissue-engineered constructs — typically expand the patient cohort to assess efficacy more rigorously. For the Rambam corneal program, reported Phase II endpoints include:
- Best-corrected visual acuity (BCVA) at 12 and 24 months post-implant
- Corneal topography and refractive index stability over the follow-up period
- Endothelial cell density as a marker of inner-layer graft viability
- Patient-reported outcomes including quality-of-vision and activities-of-daily-living measures
Manufacturing Challenges at Scale
The shift from Phase I to Phase II also brings stricter manufacturing requirements. Scaling bioprinted tissue production while maintaining batch-to-batch consistency in optical clarity and mechanical properties remains one of the field’s open engineering problems. Each patient construct requires individual cell expansion from biopsy, geometry derived from the patient’s own corneal topography imaging, and validated post-print bioreactor conditioning — a process measured in weeks, not hours.
Good Manufacturing Practice (GMP) compliance for personalized ATMPs requires that every batch be traceable and reproducible within defined tolerances, even though no two constructs are geometrically identical. Resolving that tension is where much of the current process development effort is focused.
Lessons Transferring to Musculoskeletal Bioprinting
The methodological advances from corneal bioprinting — particularly the dECM bioink formulation and bioreactor maturation protocols — are being adapted for musculoskeletal applications with different structural demands but overlapping biological logic.
Articular cartilage, like the corneal stroma, is avascular, relies on diffusion, and is composed of a highly organized extracellular matrix (primarily type II collagen and aggrecan) with relatively low cellularity. Several groups in Europe and North America are applying extrusion-based bioprinting with chondrocyte-laden bioinks to produce osteochondral constructs for focal cartilage defect repair.
Similarly, the tendon bioprinting field has drawn on protocols for aligning collagen fibers during printing — a challenge shared with the cornea’s laminated structure — to produce constructs with anisotropic mechanical properties approximating native tendon. These programs remain largely pre-clinical, but the bioink science and post-print conditioning methodology have converged significantly across tissue types.
For a broader look at how these approaches connect, see musculoskeletal tissue engineering and bioprinting.
Personalized Regenerative Medicine: The Broader Implication
The Rambam program’s reliance on patient-derived cells illustrates a shift in regenerative medicine strategy. Rather than producing universal donor tissues requiring immunosuppression, personalized constructs built from a patient’s own cells and sized to individual anatomy aim to reduce rejection risk and potentially eliminate lifelong immunosuppressive regimens.
This model is not suited to emergency indications — cell expansion from a biopsy adds weeks to the manufacturing timeline. But for elective procedures addressing chronic conditions like keratoconus or bullous keratopathy, the timeline is clinically manageable.
The personalization framework is also under active investigation for cardiac patches, tracheal segments, and auricular cartilage reconstruction. The corneal program’s Phase II data will contribute evidence to the broader ATMP regulatory framework governing all of these programs, not only the cornea-specific pathway.
What Comes Next
Phase II results from the Rambam program are anticipated in 2027–2028, with potential conditional approval in the EU under the ATMP framework contingent on those data. Parallel discussions with the FDA under Breakthrough Device Designation criteria are reported to be ongoing.
The bioprinted cornea transplant clinical trials of 2026 represent a specific data-gathering phase, not a finished technology. But the trajectory from first successful implant in October 2025 to a structured Phase II program in under a year signals that the core feasibility questions have shifted from “can this work?” to “how do we prove and scale it?” — which is a meaningful change in the clinical conversation.